About Genturadx
Genturadx is a company based in Hayward (United States) founded in 2005 was acquired by Luminex in July 2012. Genturadx has raised $4.01 million across 2 funding rounds from investors including Luminex Corporation. Genturadx operates in a competitive market with competitors including NeuMoDx, InDex Pharmaceuticals, Kryptos Biotechnologies, Quantalife and Altratech, among others.
- Headquarter Hayward, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$4.01 M (USD)
in 2 rounds
-
Latest Funding Round
$4.01 M (USD), Series A
Apr 19, 2011
- Investors
-
Employee Count
Not available
-
Acquired by
Luminex
(Jul 09, 2012)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Genturadx
Genturadx has successfully raised a total of $4.01M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $4.01 million completed in April 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Genturadx
Genturadx has secured backing from 1 investor. Prominent investors backing the company include Luminex Corporation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Developer of instruments, reagents and kits for clinical diagnostics and life science research
|
Locked | Locked | Locked |
Investor details for Genturadx
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Genturadx
Investment portfolio details for Genturadx
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Genturadx
Detailed financials for Genturadx
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Genturadx Comparisons
Peer comparison for Genturadx
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Genturadx
Genturadx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NeuMoDx, InDex Pharmaceuticals, Kryptos Biotechnologies, Quantalife and Altratech, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of a platform for low cost molecular testing
|
|
| Locked | Locked | Locked |
DNA-based immunomodulatory drugs for ulcerative colitis are developed.
|
|
| Locked | Locked | Locked |
Point-of-care molecular diagnostics are enabled by Ultrafast Photonic PCR technology.
|
|
| Locked | Locked | Locked |
Provide tools that accelerate new strategies for the diagnosis and treatment of inherited disorders, cancer, and infectious disease.
|
|
| Locked | Locked | Locked |
Next-generation molecular detection kits for viral diseases are developed.
|
|
| Locked | Locked | Locked |
Micro-droplet digital PCR and diagnostic reagents are manufactured.
|
Detailed competitors of Genturadx
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Genturadx
Complete news archive for Genturadx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Genturadx
Genturadx was founded in 2005 and raised its 1st funding round 3 years after it was founded.
Genturadx is headquartered in Hayward, United States. It is registered at Hayward, California, United States.
Genturadx is a funded company, having raised a total of $4.01M across 2 funding rounds to date.
GenturaDx was founded in 2005 in Hayward, United States, within the molecular diagnostics sector. Platforms for clinical applications are created, including the IDBox system, which incorporates single-use disposable cassettes for PCR analysis. This integrated setup processes up to 12 patient samples at once. Assays and clinical software are also under development to support operations.
Genturadx has 1 investor. Key investors include Luminex Corporation.